TY - JOUR
T1 - Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors
AU - Nguyen, Ba Khoi
AU - Maltais, Simon
AU - Perrault, Louis P.
AU - Tanguay, Jean François
AU - Tardif, Jean Claude
AU - Stevens, Louis Mathieu
AU - Borie, Mélanie
AU - Harel, François
AU - Mansour, Samer
AU - Noiseux, Nicolas
N1 - Funding Information:
Acknowledgements We acknowledge Dr. D.C. Roy (Hôpital Maisonneuve-Rosemont) for his contribution in flow cytometric analyses. We thank M.P. Mathieu, E. Reny-Nolin, S. Gilligan, P. Geoffroy, and D. Lauzier for their precious help in this study and Dr Yan Fen Shi for the echocardiographic analysis. Drs. Noiseux and Perrault are scholars of Fonds de la Recherche en Santé du Québec (FRSQ). Dr. Noiseux and Perrault are supported by the Heart and Stroke Foundation of Québec, and Department of Surgery, Université de Montréal. Dr Stevens is supported by the Canadian Institutes of Health Research (CIHR).
Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2010/10
Y1 - 2010/10
N2 - Transplantation of mesenchymal stem cells (MSC) improves repair and function recovery following myocardial infarction (MI), but underlying mechanisms remain to be elucidated. We hypothesize that MSC could achieve protection by paracrine effects through released mediators rather than direct cardiac regeneration. We sought to characterize the effects of MSC-secreted growth factors on extent of early recovery from MI. Swine subjected to acute MI by temporary balloon occlusion of the left anterior descending coronary artery using percutaneous techniques received intracoronary injection of either concentrated MSC-derived growth factors or control medium. Animals were killed at 7 days to evaluate early effects. Treatment with MSC-derived factors significantly reduced cardiac troponin-T elevation and improved echocardiographic parameters, including fractional area shortening, stroke volume, cardiac output, and wall motion score index. Quantitative evaluation of fibrosis by Verhoff staining revealed a reduction of the fibrotic area in the infarcted zone. Similarly, Masson's trichrome staining revealed reduced myocardial damage as demonstrated by areas of relatively preserved myocardium in the infarcted area. TUNEL assay demonstrated less cardiomyocyte apoptosis. Protein array detected the presence of angiogenic (vascular endothelial growth factor, endothelin, and epiregulin), anti-apoptotic (Galectin-3, Smad-5, sRFP-1, and sRFP-4) and anti-remodeling factors. Reverse transcription polymerase chain reaction confirmed the expression of these factors. In summary, a single intracoronary injection of concentrated biologically active factors secreted by MSC could achieve early protection of ischemic myocardium and improve cardiac repair and contractility. MSC-derived growth factors injection (rather than MSC themselves) should be evaluated as a novel therapy to treat ischemic heart disease, avoiding many practical and technical issues of cell therapy.
AB - Transplantation of mesenchymal stem cells (MSC) improves repair and function recovery following myocardial infarction (MI), but underlying mechanisms remain to be elucidated. We hypothesize that MSC could achieve protection by paracrine effects through released mediators rather than direct cardiac regeneration. We sought to characterize the effects of MSC-secreted growth factors on extent of early recovery from MI. Swine subjected to acute MI by temporary balloon occlusion of the left anterior descending coronary artery using percutaneous techniques received intracoronary injection of either concentrated MSC-derived growth factors or control medium. Animals were killed at 7 days to evaluate early effects. Treatment with MSC-derived factors significantly reduced cardiac troponin-T elevation and improved echocardiographic parameters, including fractional area shortening, stroke volume, cardiac output, and wall motion score index. Quantitative evaluation of fibrosis by Verhoff staining revealed a reduction of the fibrotic area in the infarcted zone. Similarly, Masson's trichrome staining revealed reduced myocardial damage as demonstrated by areas of relatively preserved myocardium in the infarcted area. TUNEL assay demonstrated less cardiomyocyte apoptosis. Protein array detected the presence of angiogenic (vascular endothelial growth factor, endothelin, and epiregulin), anti-apoptotic (Galectin-3, Smad-5, sRFP-1, and sRFP-4) and anti-remodeling factors. Reverse transcription polymerase chain reaction confirmed the expression of these factors. In summary, a single intracoronary injection of concentrated biologically active factors secreted by MSC could achieve early protection of ischemic myocardium and improve cardiac repair and contractility. MSC-derived growth factors injection (rather than MSC themselves) should be evaluated as a novel therapy to treat ischemic heart disease, avoiding many practical and technical issues of cell therapy.
KW - Cardiac Function
KW - Cellular Therapy
KW - Growth Factors
KW - Myocardial Ischemia
KW - Stem Cells
UR - http://www.scopus.com/inward/record.url?scp=77958087304&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958087304&partnerID=8YFLogxK
U2 - 10.1007/s12265-010-9171-0
DO - 10.1007/s12265-010-9171-0
M3 - Article
C2 - 20559784
AN - SCOPUS:77958087304
SN - 1937-5387
VL - 3
SP - 547
EP - 558
JO - Journal of cardiovascular translational research
JF - Journal of cardiovascular translational research
IS - 5
ER -